Bisphosphonates Hinder Osteoblastic/osteoclastic Differentiation in the Maxillary Sinus Mucosa-derived Stem Cells

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2017 Dec 1

PMID 29188452

Citations 6

Authors

Jun Zhang

Jaesuh Park

Jung-Woo Lee

Yong-Dae Kwon

Eun-Cheol Kim

Affiliations

Soon will be listed here.

Abstract

Objectives: Although bisphosphonates (BPs) are known to be associated with osteonecrosis of the maxilla, the precise effects of BPs on bone metabolism in human maxillary sinus mucosal cells (HMSMCs) are not yet known. The purposes of this study were to examine the effects of the BPs zoledronate (ZOL) and alendronate (ALN) on osteoblastic and osteoclastic differentiation in HMSMCs and to investigate the signaling pathways involved.

Materials And Methods: The effects of ZOL and ALN were assessed for osteoblast differentiation by alkaline phosphatase (ALP) activity, alizarin red staining, and RT-PCR for genes encoding Runx2 and osterix. Receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow macrophages (BMMs) was also examined.

Results: ZOL and ALN both suppressed osteoblastic differentiation, as evidenced by their effects on ALP activity, mineralization nodule formation, and the mRNA expression levels of osteoblastic transcript factors. The RANKL/osteoprotegerin ratio in HMSMCs was increased by ALN, whereas ZOL had the opposite effect. Conditioned medium obtained from ALN-treated HMSMCs stimulated osteoclast formation and upregulated NFATc1 expression, whereas conditioned medium from ZOL-treated cells did not. ALN was more cytotoxic and stimulated apoptosis more strongly than ZOL. BPs decreased the protein levels of the non-canonical Wnt signaling protein Wnt5a and calmodulin-dependent kinase II. Moreover, recombinant human Wnt5a reversed the effects of BPs on osteoblastic and osteoclastic differentiation.

Conclusion: This study is the first demonstration that BPs exert negative effects on osteoblastic and osteoclastic processes via the non-canonical Wnt pathway in HMSMSCs.

Clinical Relevance: It suggests that patients taking BPs during the period of maxillary sinus lifting and amentation should be given special attention.

Citing Articles

Effects of total flavonoids of Rhizoma Drynariae on biochemical indicators of bone metabolism: a systematic review and meta-analysis.

Li W, Zhang Z, Li Y, Wu Z, Wang C, Huang Z Front Pharmacol. 2024; 15:1443235.

PMID: 39359242 PMC: 11445651. DOI: 10.3389/fphar.2024.1443235.

Bisphosphonate-incorporated coatings for orthopedic implants functionalization.

Zhang J, Bai H, Bai M, Wang X, Li Z, Xue H Mater Today Bio. 2023; 22:100737.

PMID: 37576870 PMC: 10413202. DOI: 10.1016/j.mtbio.2023.100737.

Nitrogen-Containing Bisphosphonates Downregulate Cathepsin K and Upregulate Annexin V in Osteoclasts Cultured .

Bautista-Carbajal A, Villanueva-Arriaga R, Paez-Arenas A, Masso-Rojas F, Frechero Molina N, Garcia-Lopez S Int J Dent. 2023; 2023:2960941.

PMID: 36866025 PMC: 9974278. DOI: 10.1155/2023/2960941.

How zoledronic acid improves osteoporosis by acting on osteoclasts.

Wang B, Zhan Y, Yan L, Hao D Front Pharmacol. 2022; 13:961941.

PMID: 36091799 PMC: 9452720. DOI: 10.3389/fphar.2022.961941.

Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.

Huang X, Liu C, Shi X, Cheng Y, Zhou Q, Li J Mol Med Rep. 2021; 25(2).

PMID: 34935053 PMC: 8711024. DOI: 10.3892/mmr.2021.12575.

References

Yamada J, Tsuno N, Kitayama J, Tsuchiya T, Yoneyama S, Asakage M . Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res. 2008; 151(1):115-20. DOI: 10.1016/j.jss.2008.01.031. View

Inoue Y, Hisa I, Seino S, Kaji H . Alendronate induces mineralization in mouse osteoblastic MC3T3-E1 cells: regulation of mineralization-related genes. Exp Clin Endocrinol Diabetes. 2010; 118(10):719-23. DOI: 10.1055/s-0030-1249084. View

Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M . Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002; 8(5):1080-4. View

Amaral J, Xavier J, Steer C, Rodrigues C . The role of p53 in apoptosis. Discov Med. 2010; 9(45):145-52. View

Moreau M, Guillet C, Massin P, Chevalier S, Gascan H, Basle M . Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol. 2006; 73(5):718-23. DOI: 10.1016/j.bcp.2006.09.031. View

Duarte P, Gurgel B, Sallum A, Filho G, Sallum E, Nociti Jr F . Alendronate therapy may be effective in the prevention of bone loss around titanium implants inserted in estrogen-deficient rats. J Periodontol. 2005; 76(1):107-14. DOI: 10.1902/jop.2005.76.1.107. View

Pabst A, Kruger M, Ziebart T, Jacobs C, Walter C . Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro. Clin Oral Investig. 2015; 19(7):1625-33. DOI: 10.1007/s00784-014-1394-z. View

Bell B, Bell R . Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg. 2008; 66(5):1022-4. DOI: 10.1016/j.joms.2007.12.040. View

Viereck V, Emons G, Lauck V, Frosch K, Blaschke S, Grundker C . Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002; 291(3):680-6. DOI: 10.1006/bbrc.2002.6510. View

10.

Narongroeknawin P, Danila M, Humphreys Jr L, Barasch A, Curtis J . Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist. 2010; 30(2):77-82. PMC: 4097110. DOI: 10.1111/j.1754-4505.2009.00128.x. View

11.

Starck W, EPKER B . Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants. 1995; 10(1):74-8. View

12.

Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M . Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer. 2005; 104(1):118-25. DOI: 10.1002/cncr.21104. View

13.

Bruzzaniti A, Baron R . Molecular regulation of osteoclast activity. Rev Endocr Metab Disord. 2006; 7(1-2):123-39. DOI: 10.1007/s11154-006-9009-x. View

14.

Eriksen E . Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010; 11(4):219-27. PMC: 3028072. DOI: 10.1007/s11154-010-9153-1. View

15.

Naidu A, Dechow P, Spears R, Wright J, Kessler H, Opperman L . The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 106(1):5-13. DOI: 10.1016/j.tripleo.2008.03.036. View

16.

Srouji S, Kizhner T, Ben David D, Riminucci M, Bianco P, Livne E . The Schneiderian membrane contains osteoprogenitor cells: in vivo and in vitro study. Calcif Tissue Int. 2008; 84(2):138-45. DOI: 10.1007/s00223-008-9202-x. View

17.

Basso F, Turrioni A, Hebling J, de Souza Costa C . Zoledronic acid inhibits human osteoblast activities. Gerontology. 2013; 59(6):534-41. DOI: 10.1159/000351194. View

18.

Dunford J, Thompson K, Coxon F, Luckman S, Hahn F, Poulter C . Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296(2):235-42. View

19.

Pan B, Farrugia A, To L, Findlay D, Green J, Lynch K . The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res. 2004; 19(1):147-54. DOI: 10.1359/jbmr.2004.19.1.147. View

20.

Dobnig H, Hofbauer L, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A . Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int. 2006; 17(5):693-703. DOI: 10.1007/s00198-005-0035-4. View